GU Cancers 2024 | Managing renal cell carcinoma after progressing on checkpoint inhibitors

David Braun, MD, PhD, Yale School of Medicine, New Haven, CT, delves into the treatment options available for patients with renal cell carcinoma (RCC), who progress on checkpoint inhibitors. Whilst there are several strategies such as TKI and HIF2α inhibition, these options are not curative. Dr Braun additionally discusses the role of checkpoint inhibitor rechallenge and findings from the Phase III CONTACT-03 trial (NCT04338269) of atezolizumab plus cabozantinib versus cabozantinib monotherapy. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.